REGULAR GENETIC COUNSELING AND DNA-DIAGNOSTICS OF MARFAN SYNDROME IN THE WORK OF FEDERAL SURGERY INSTITUTION
https://doi.org/10.15829/1560-4071-2016-10-7-14
Abstract
Aim. To invent a complex approach to patients with “marfanoid phenotype” undergoing surgery, applying the DNA-diagnostics of the gene FBN1 and medical genetic counseling.
Material and methods. In the group of 37 patients with suspected Marfan syndrome we conducted analysis of coding exones and attached enthrones of the gene FBN1 with highly performing sequencing on platform IonTorrent.
Results. After mutation screening in the sequences of gene FBN1, in 25 patients we confirmed the Marfan syndrome, and four of genetic mutation carriers did not have complete Ghent criteria. All genetic variants were analyzed and were applied at the stage of surgery planning for maximum radical result of surgical treatment and for medical genetic counseling of the families.
Conclusion. The analysis performed, of clinical presentation, surgery indications and spectrum of post-operation complications in Marfan syndrome patients.
About the Authors
V. A. Rumyantseva
V. B . Petrovskiy Russian National Research Centre of Surgery, Moscow, Russia
Russian Federation
Russian Federation
Yu. A. Rogozhina
V. B . Petrovskiy Russian National Research Centre of Surgery, Moscow, Russia
Russian Federation
Russian Federation
A. A. Bukaeva
V. B . Petrovskiy Russian National Research Centre of Surgery, Moscow, Russia
Russian Federation
Russian Federation
D. V. Bazarov
V. B . Petrovskiy Russian National Research Centre of Surgery, Moscow, Russia
Russian Federation
Russian Federation
E. R. Charchyan
V. B . Petrovskiy Russian National Research Centre of Surgery, Moscow, Russia
Russian Federation
Russian Federation
E. V. Zaklyazminskaya
V. B . Petrovskiy Russian National Research Centre of Surgery, Moscow, Russia
Russian Federation
Russian Federation
References
1. Pyeritz RE.Recent progress in understanding the natural and clinical histories of the Marfan syndrome. Trends Cardiovasc Med. 2016 Jul;26(5):423-8.
2. Carrel T, Beyeler L, Schnyder A, et al. Reoperations and late adverse outcome in Marfan patients following cardiovascular surgery. Eur J Cariothorac Surg 2004; 25: 671-5.
3. Murphy-Ryan M, Psychogios A, Lindor NM. Hereditary disorders of connective tissue: A guide to the emerging differential diagnosis. Genet Med 2010; 12(6): 344-54.
4. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases Eur Heart Jour 2014; Nov1; 35(41): 2873-926.
5. Loeys BL, Dietz HC, Braverman AC et al. The revised Ghent nosology for the Marfan syndrome; J Med Genet; 2010; 47: 476-85.
6. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm; 2011; Aug;8(8): 1308-39.
7. Inácio A, Silva AL, Pinto J, et al. Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay. J Biol Chem. 2004 Jul 30; 279(31): 32170-80.
8. Faivre L, Collod-Beroud G, Callewaert B, et al. Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation; Eur J Hum Genet; 2009; 17; 491-501.
9. Olivieri J, Smaldone S, Ramirez F. Fibrillin assemblies: extracellular determinants of tissue formation and fibrosis. Fibrogenesis & Tissue Repair. 2010; 3-24.
10. Marfan Universal Database — www.umd.be (15/10/2016).
11. Jensen SA, Aspinall G, Handford PA. C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assembly through linkage to domains cbEGF41-43. PNAS July 15, 2014; 111, 28:10155-60.
12. Bernhardt AMJ, Treede H, Rybczynski M, et al. David-operation vs. Bentall-procedure in patients with Marfan syndrome Thorac cardiovasc Surg 2010; 58-V104.
13. Kirschner R, Hubmacher D, Iyengar G, et al. Classical and Neonatal Marfan Syndrome Mutations in Fibrillin-1 Cause Differential Protease Susceptibilities and Protein Function; The Journal of biological chemistry, 2011; 286, 37; 1; 32810-23.
14. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014; 371: 2061-71.
Review
For citations:
Rumyantseva V.A., Rogozhina Yu.A., Bukaeva A.A., Bazarov D.V., Charchyan E.R., Zaklyazminskaya E.V. REGULAR GENETIC COUNSELING AND DNA-DIAGNOSTICS OF MARFAN SYNDROME IN THE WORK OF FEDERAL SURGERY INSTITUTION. Russian Journal of Cardiology. 2016;(10):7-14. (In Russ.) https://doi.org/10.15829/1560-4071-2016-10-7-14
Views:
1062
Email this article 